ReviewThe Journal of clinical endocrinology and metabolism2026
Endogenous Testosterone, Testosterone Treatment, and Cardiovascular Health Outcomes in Men.
Review in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- System-level clustering of testosterone-related biomarkers identifies high-risk aging profiles linked to inflammation and renal function.Communications medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whether lower testosterone concentrations in aging men predispose to poorer health, particularly cardiovascular disease (CVD), remains controversial. This narrative review summarizes the relationships between testosterone and cardiovascular health outcomes, based on observational and interventional studies. Cross-sectional analyses show that lower endogenous testosterone concentrations are found in men with preexisting CVD, but larger influences are age > 70 years, higher body mass index, and medical comorbidities such as diabetes or cancer. In the United Kingdom Biobank, the largest prospective cohort study to date, lower endogenous testosterone concentrations were associated with higher risk of all-cause mortality, but not incident cardiovascular events or CVD deaths. In an individual participant data meta-analysis of prospective cohort studies with testosterone measured using mass spectrometry, there were nonlinear associations of baseline testosterone concentrations with higher all-cause and cardiovascular mortality, with these risks increasing below thresholds of testosterone < 7.4 nmol/L (213 ng/dL) and < 5.3 nmol/L (153 ng/dL), respectively. In the randomized, placebo-controlled T4DM trial involving men with dysglycemia, testosterone treatment on a background of lifestyle intervention reduced risk of type 2 diabetes mellitus after 2 years. The TRAVERSE cardiovascular safety trial, conducted in men with CVD or multiple risk factors, found no increased risk of major adverse cardiovascular events in men randomized to testosterone treatment vs placebo, with average follow-up of 3 years. Based on epidemiological studies, and the results of T4DM and TRAVERSE, additional studies are needed to confirm long-term cardiovascular safety, and explore possible cardiovascular benefits related to changes in body composition and cardiometabolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.